ALLY BRIDGE GROUP NY LLC
Q2 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001822947
· CRD 291072
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q1 2021
$82.6M Reported Value Total
ALLY BRIDGE GROUP (NY) LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $146,724,487, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $340.7M gross asset value
Hedge Fund: $340.7M
Source: Form ADV filed 2026-03-31
Reported value
$82.6M
Quarter over quarter
+8.3%
Holdings
17
Top-10 concentration
82.9%
Filing Structure
Reports holdings for
- Yu Fan · File #028-20833 · since Q1 2021 · declared by one filing
- Fan Yu (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
Key People
Form ADV owners & control persons
Fan Yu
SHAREHOLDER AND DIRECTOR
Slanix Paul T Alex
PRESIDENT & PORTFOLIO MANAGER
Michael Novick Bendetson
COO, HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $82.6M |
| Positions | 17 |
| Change in reported value | +8.2% |
| New positions | 8 |
| Exited positions | 9 |
| Position turnover | 65.4% |
| Top-10 concentration | 82.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
14 | $76.0M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
23 | $113.1M |
|
Q1 2026 13F
Filed May 18, 2026
|
21 | $123.8M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
13 | $96.0M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
18 | $164.2M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
24 | $120.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
28 | $110.9M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
30 | $116.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
29 | $186.8M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
25 | $167.9M |
|
Q1 2024 13F
Filed May 15, 2024
|
22 | $179.9M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
22 | $167.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
19 | $85.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
17 | $82.6M |
|
Q1 2023 13F
Filed May 15, 2023
|
18 | $76.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
30 | $102.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
39 | $151.5M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
22 | $109.7M |
|
Q1 2022 13F
Filed May 16, 2022
|
21 | $134.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
30 | $286.1M |
4 earlier quarters on file — choose one from the quarter menu above.
Top 17 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RETA REATA PHARMACEUTICALS INC-A | $10.8M | 13.04% |
| 2 | VRNA VERONA PHARMA PLC - ADR | $10.3M | 12.49% |
| 3 | XENE XENON PHARMACEUTICALS INC | $10.3M | 12.45% |
| 4 | CYTK CYTOKINETICS INC | $7.3M | 8.83% |
| 5 | GERN GERON CORP | $6.8M | 8.25% |
| 6 | MRUS MERUS NV | $5.2M | 6.35% |
| 7 | VRDN VIRIDIAN THERAPEUTICS INC | $4.8M | 5.81% |
| 8 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $4.7M | 5.65% |
| 9 | MRNS MARINUS PHARMACEUTICALS INC | $4.2M | 5.14% |
| 10 | BDTX BLACK DIAMOND THERAPEUTICS I | $4.0M | 4.89% |
| 11 | PRAX PRAXIS PRECISION MEDICINES I | $3.7M | 4.46% |
| 12 | JSPR JASPER THERAPEUTICS INC | $3.4M | 4.18% |
| 13 | CMPX COMPASS THERAPEUTICS INC | $2.9M | 3.52% |
| 14 | MDVL MEDAVAIL HOLDINGS INC | $1.4M | 1.75% |
| 15 | MDXH MDXHEALTH SA-ADR | $1.2M | 1.44% |
| 16 | CNTX CONTEXT THERAPEUTICS INC | $1.0M | 1.27% |
| 17 | RPID RAPID MICRO BIOSYSTEMS INC-A | $403.3K | 0.49% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.